Gavin Hackett

Gavin Hackett

Part-Qualified Attorney

gavin.hackett@abelimray.com
+44(0) 2072 429984

Academic qualifications:
BSc. Biochemistry and Biological Chemistry, University of Nottingham
Ph.D Chemical Biology, University of Nottingham

Gavin joined Abel + Imray in 2016 and is based in the London Office. Before joining the firm, he spent 4 years working as a research scientist in biotherapeutic drug discovery for a global pharmaceutical company. During this time, his work focussed on the design, purification and characterisation of novel neurotoxin-based therapeutics, and he was also the industrial supervisor for a structural biology PhD student. His research contributed to the selection of two drug candidates and he is an inventor on several patent applications.

His Ph.D. was part of a collaboration with a global biotechnology company and focused on the application of cell penetrating peptides for the intracellular delivery of therapeutic antibody fragments. He is a member of the Royal Society of Biology and the Biochemical Society.  

Gavin has significant experience in protein engineering, including directed evolution and rational protein design using structure and bioinformatics-guided techniques, and bioconjugation and chemical biology, including experience with a range of protein modification techniques, and expertise using chemical and enzyme-mediated site-specific protein modification techniques for the synthesis of protein conjugates. He also has detailed knowledge of modern molecular biology techniques, including a wide range of modern PCR, sub-cloning, and site-directed mutagenesis technologies. This expertise allows Gavin to quickly gain a deep understanding of his clients’ inventions, be they universities and spin-out companies or major multinationals.    

He is involved in drafting and prosecution work, primarily in the biotechnology and chemical fields, including antibodies and antibody-drug conjugates, hormones and bioactive compounds, protein-matrix vaccines, T-cell therapies, stabilised pharmaceutical formulations, and dosage regimens.